Skip to content

Clinical efficacy analysis of oral ferrous sulfate and folic acid tablets in patients with iron deficiency anemia during pregnancy

Clinical efficacy analysis of oral ferrous sulfate and folic acid tablets in patients with iron deficiency anemia during pregnancy: a prospective, randomized, parallel controlled clinical study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105898
Enrollment
Unknown
Registered
2025-07-14
Start date
2025-07-15
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate iron deficiency anemia during pregnancy

Interventions

Study group:Take oral compound ferrous sulfate folic acid tablets
control group:Take ferrous succinate tablets

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
24 Years to 44 Years

Inclusion criteria

Inclusion criteria: 1.It meets the diagnostic criteria of mild and moderate pregnancy IDA in accordance with the Guidelines for “diagnosis and treatment of iron deficiency and iron deficiency anemia during pregnancy”; 2.Age 24-44; 3.Pregnancy 24-28 weeks, average pregnancy 26 weeks; 4.single pregnancy; 5.The patients and their families are aware of the contents involved in this study and participate voluntarily;

Exclusion criteria

Exclusion criteria: 1.Anemia in early pregnancy; 2.The patient was complicated with gestational diabetes mellitus, preeclampsia and other pregnancy complications; 3.The patient has a history of digestive system, liver, kidney, heart, brain and other diseases; 4.Patients with anemia caused by malignant tumors; 5.Allergy to the study drug; 6.Severe or very severe pregnancy iron deficiency anemia requires transfusion of concentrated red blood cells or intravenous iron supplementation; 7.People with combined immune system diseases and mental illness; 8.Those who fail to take medicine regularly due to various factors; 9.Transfer to another hospital or withdrawal of the investigator;

Design outcomes

Primary

MeasureTime frame
Hb level;

Secondary

MeasureTime frame
Maternal complications;Symptoms of anemia;The level of ferritin;

Countries

China

Contacts

Public ContactSun Yu

Peking University First Hospital

sunyu1705@126.com+86 10 8357 2177

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026